Physician profile
Mark L Goldstein
NPI 1487758033
$4,797.78
in general payments reported to CMS, 2019-2025
42 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,176 · 2020: $587 · 2021: $21.35 · 2023: $14.00.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $14.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $14.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $417.84 | 2019-2021 | |
| Genentech USA, INC. | $351.44 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $337.14 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $249.74 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $240.27 | 2019 | |
| Genzyme Corporation | $236.44 | 2019-2020 | |
| Taiho Oncology, INC. | $213.26 | 2019-2020 | |
| Seagen INC. | $207.46 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $202.06 | 2019-2020 | |
| Celgene Corporation | $186.41 | 2019 | |
| Incyte Corporation | $177.49 | 2019-2020 | |
| Amgen INC. | $175.11 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $141.70 | 2019 | |
| Puma Biotechnology, INC. | $139.14 | 2019 | |
| Lilly USA, LLC | $134.67 | 2019-2020 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Goldstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.